Germ-line and somatic PTPN11 mutations in human disease

被引:118
作者
Tartaglia, M
Gelb, BD
机构
[1] Ist Super Sanita, Dipartimento Biol Cellulare & Neurosci, I-00161 Rome, Italy
[2] Mt Sinai Sch Med, Dept Pediat, New York, NY USA
[3] Mt Sinai Sch Med, Dept Human Genet, New York, NY USA
关键词
PTPN11; SHP-2; Noonan syndrome; LEOPARD syndrome; juvenile myelomonocytic leukemia; acute leukemia; myelodysplastic syndromes; gain-of-function mutations; genotype-phenotype correlation;
D O I
10.1016/j.ejmg.2005.03.001
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Reversible protein tyrosyl phosphorylation of cell surface receptors and downstream intracellular transducers is a major regulatory mechanism used to modulate cellular responses to extracellular stimuli, and its deregulation frequently drives aberrant cell proliferation, survival and/or differentiation. SHP-2 is a cytoplasmic Src-homology 2 domain-containing protein tyrosine phosphatase that plays an important role in intracellular signaling and is required during development and hematopoiesis. Germ-line missense mutations in PTPN11, the gene coding SHP-2, have been discovered as a major molecular event underlying Noonan syndrome, an autosomal dominant trait characterized by short stature, dysmorphic facies, and congenital heart defects, as well as in other closely related developmental disorders. More recently, a distinct class of missense mutations in the same gene has been identified to occur as a somatic event contributing to myeloid and lymphoid malignancies. This review focuses on the role of SHP-2 in signal transduction, development and hematopoiesis, as well as on the consequences of SHP-2 gain-of-function. (c) 2005 Elsevier SAS. All rights reserved.
引用
收藏
页码:81 / 96
页数:16
相关论文
共 85 条
[1]   A WIDELY EXPRESSED HUMAN PROTEIN-TYROSINE PHOSPHATASE CONTAINING SRC HOMOLOGY-2 DOMAINS [J].
AHMAD, S ;
BANVILLE, D ;
ZHAO, ZZ ;
FISCHER, EH ;
SHEN, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (06) :2197-2201
[2]   NOONAN SYNDROME [J].
ALLANSON, JE .
JOURNAL OF MEDICAL GENETICS, 1987, 24 (01) :9-13
[3]   Protein tyrosine phosphatases in the human genome [J].
Alonso, A ;
Sasin, J ;
Bottini, N ;
Friedberg, I ;
Friedberg, I ;
Osterman, A ;
Godzik, A ;
Hunter, T ;
Dixon, J ;
Mustelin, T .
CELL, 2004, 117 (06) :699-711
[4]   A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage [J].
Andersen, JN ;
Jansen, PG ;
Echwald, SM ;
Mortensen, OH ;
Fukada, T ;
Del Vecchio, R ;
Tonks, NK ;
Moller, NPH .
FASEB JOURNAL, 2004, 18 (01) :8-30
[5]   Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation [J].
Araki, T ;
Mohi, MG ;
Ismat, FA ;
Bronson, RT ;
Williams, IR ;
Kutok, JL ;
Yang, WT ;
Pao, LI ;
Gilliland, DG ;
Epstein, JA ;
Neel, BG .
NATURE MEDICINE, 2004, 10 (08) :849-857
[6]   Juvenile myelomonocytic leukemia [J].
Arico, M ;
Biondi, A ;
Pui, CH .
BLOOD, 1997, 90 (02) :479-488
[7]   Occurrence of myeloproliferative disorder in patients with Noonan syndrome [J].
BaderMeunier, B ;
Tchernia, G ;
Mielot, F ;
Fontaine, JL ;
Thomas, C ;
Lyonnet, S ;
Lavergne, JM ;
Dommergues, JP .
JOURNAL OF PEDIATRICS, 1997, 130 (06) :885-889
[8]   Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia [J].
Bentires-Alj, M ;
Paez, JG ;
David, FS ;
Keilhack, H ;
Halmos, B ;
Naoki, K ;
Maris, JM ;
Richardson, A ;
Bardelli, A ;
Sugarbaker, DJ ;
Richards, WG ;
Du, JY ;
Girard, L ;
Minna, JD ;
Loh, ML ;
Fisher, DE ;
Velculescu, VE ;
Vogelstein, B ;
Meyerson, M ;
Sellers, WR ;
Neel, BG .
CANCER RESEARCH, 2004, 64 (24) :8816-8820
[9]  
Bertola D R, 2000, Arq Bras Cardiol, V75, P409, DOI 10.1590/S0066-782X2000001100005
[10]   Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation [J].
Bertola, DR ;
Pereira, AC ;
de Oliveira, PSL ;
Kim, CA ;
Krieger, JE .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2004, 130A (04) :378-383